Optimizing Gastroenterology CoverMyMeds Integration for Specialty Drug PAs

Klivira streamlines gastroenterology CoverMyMeds integration, automating electronic prior authorizations for high-cost specialty drugs and complex procedures common in GI practices.

For revenue cycle directors and prior authorization coordinators in gastroenterology, managing the high volume of specialty drug PAs can be a significant operational burden. Integrating with electronic prior authorization (ePA) platforms like CoverMyMeds is crucial, but the nuances of GI-specific medications and procedures demand a tailored approach to truly optimize efficiency and reduce denial rates.

The Unique Prior Authorization Landscape in Gastroenterology

Gastroenterology practices face a distinct set of prior authorization challenges, primarily driven by chronic conditions requiring high-cost specialty drugs and advanced diagnostic or therapeutic procedures. The continuous management of conditions like Crohn's disease and ulcerative colitis necessitates frequent PA submissions, making efficient workflows critical for patient access and revenue integrity.

Key GI Medications and Procedures Requiring CoverMyMeds ePA

**IBD Biologics:** TNF inhibitors (adalimumab/Humira, infliximab/Remicade), integrin inhibitors (vedolizumab/Entyvio), IL-12/23 inhibitors (ustekinumab/Stelara, risankizumab/Skyrizi), JAK inhibitors (tofacitinib/Xeljanz, upadacitinib/Rinvoq), S1P modulators (ozanimod/Zeposia, etrasimod/Velsipity).
**Hepatitis C DAAs:** sofosbuvir-velpatasvir (Epclusa), glecaprevir-pibrentasvir (Mavyret).
**Specialty Drugs for Functional GI Disorders:** eluxadoline (Viberzi), prucalopride (Motegrity), linaclotide (Linzess), plecanatide (Trulance).
**Advanced Imaging:** MRCP, MR enterography, CT enterography for IBD assessment.
**Endoscopic Procedures:** Capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, EUS for specific indications.

Streamlining Specialty Drug ePA through CoverMyMeds Integration

CoverMyMeds is a leading platform for electronic prior authorization, primarily facilitating pharmacy benefit drug PAs via the NCPDP SCRIPT standard. For gastroenterology, this is particularly relevant for self-administered IBD biologics, Hepatitis C DAAs, and specialty functional GI drugs. Klivira's integration enhances this by automating data extraction from the EMR, populating CoverMyMeds forms, and managing the submission and tracking process, reducing manual data entry and improving submission accuracy.

Addressing GI-Specific Documentation and Denial Challenges

**Compliance with Clinical Guidelines:** Klivira's platform incorporates logic informed by ACG, AGA, and AASLD guidelines, ensuring submissions meet payer criteria for conditions like IBD and Hepatitis C.
**Detailed Clinical Data Requirements:** Automated extraction of diagnosis confirmation (endoscopic, imaging, histologic), disease severity scores (Mayo score, CDAI), prior conventional therapy trials, and TB/hepatitis screening documentation.
**Managing Step Therapy:** Automated identification and adherence to payer-specific step therapy protocols for IBD biologics, including biosimilar substitution requirements.
**Treatment-Naive vs. Experienced Classification:** Precise classification for IBD biologics and Hep C DAAs, critical for correct PA pathway determination and avoiding denials.
**Chronic Re-authorization Workflow:** Proactive management of periodic re-authorizations for chronic IBD biologic treatments, ensuring continuous patient access.

Klivira's Approach to GI CoverMyMeds Integration

Klivira's platform provides a comprehensive solution for gastroenterology covermymeds integration. By connecting directly to your EMR, we automate the assembly of required clinical documentation, apply payer-specific policy logic for GI indications, and manage the entire ePA lifecycle through CoverMyMeds and other payer channels. This ensures that even complex GI PAs, from biologics to advanced procedures, are handled efficiently and accurately.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for GI biologics when integrating with CoverMyMeds?

Klivira's platform intelligently routes prior authorizations based on the administration mode of biologic agents. While CoverMyMeds primarily handles pharmacy benefit drugs, Klivira can identify whether a GI biologic is self-administered (pharmacy benefit, routed to CMM) or provider-administered (medical benefit, routed to appropriate X12 278 or payer portal), ensuring the correct pathway is always used.

Can Klivira integrate with my EMR to pull specific GI clinical data for CoverMyMeds submissions?

Yes, Klivira offers robust EMR integration capabilities, including SMART on FHIR. This allows us to automatically extract critical GI-specific clinical data, such as Mayo scores, CDAI, endoscopy reports, imaging results, and medication histories, directly from your EMR to populate CoverMyMeds forms and support medical necessity documentation.

What are the most common GI drugs requiring ePA via CoverMyMeds that Klivira supports?

Klivira supports a wide range of GI drugs requiring ePA via CoverMyMeds, with a strong focus on high-volume specialty biologics for IBD like Humira, Stelara, Skyrizi, and Entyvio. We also handle Hepatitis C direct-acting antivirals (e.g., Epclusa, Mavyret) and specialty drugs for functional GI disorders such as Viberzi, Motegrity, Linzess, and Trulance.

How does Klivira help with re-authorizations for chronic GI conditions like IBD?

Klivira automates the periodic re-authorization workflow common for chronic GI conditions requiring biologics. Our system tracks authorization expiry dates, proactively initiates re-authorization requests, and compiles updated clinical documentation to demonstrate ongoing medical necessity, minimizing lapses in patient care and reducing administrative burden.

Does Klivira's integration with CoverMyMeds address biosimilar substitution policies for GI biologics?

Yes, Klivira's payer-policy logic is designed to navigate the variability in biosimilar substitution mandates across different payers. Our system helps ensure that prior authorization requests for GI biologics comply with specific payer requirements, including initial biosimilar trials or documentation for brand-name agent medical necessity, reducing denials related to step therapy.